Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.

Leukemia·2026

Same author

No evidence for sleep-dependent memory generalization in a large online sample.

bioRxiv : the preprint server for biology·2026

Same author

Remodeling of Mitochondrial Networks: Cellular Adaptation and Microenvironmental Reprogramming in Hematologic Malignancies.

Blood cancer discovery·2026

Same author

Odor-Cued Targeted Reactivation Was Unable to Selectively Benefit Declarative Memories During Sleep.

Journal of sleep research·2026

Same author

Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma.

Discover oncology·2025

Same author

Recent advances in S-palmitoylation and its emerging roles in human diseases.

Journal of hematology & oncology·2025

Search research articles

Related Experiment Video

Updated: Aug 12, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations.

Shunfeng Hu^1,2, Tiange Lu¹, Juanjuan Shang¹

¹Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China.

Cell Death Discovery

|February 1, 2023

Summary

Prostaglandin D2 (PGD2) shows dual roles in diffuse large B-cell lymphoma (DLBCL). High PGD2 levels may serve as a therapeutic strategy, impacting prognosis and enhancing drug efficacy in DLBCL patients.

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

Related Experiment Videos

Last Updated: Aug 12, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

Area of Science:

Oncology
Immunology
Biochemistry

Background:

Prostaglandin D2 (PGD2), an arachidonic acid metabolite, is linked to allergic responses, parasitic infections, and tumor development.
The specific roles and mechanisms of PGD2 in diffuse large B-cell lymphoma (DLBCL) remain unclear.

Purpose of the Study:

To investigate the role of PGD2 and its receptor CRTH2 in DLBCL.
To explore the potential of PGD2 as a prognostic biomarker and therapeutic target in DLBCL.

Main Methods:

Serum PGD2 levels and CRTH2 expression were analyzed in DLBCL patients.
The effects of varying PGD2 concentrations on DLBCL cell progression, proliferation, apoptosis, cell cycle, and invasion were assessed.
The impact of high-concentration PGD2 on ROS-mediated DNA damage and drug cytotoxicity was evaluated.
The interaction between HDAC inhibitors, CRTH2 inhibitors, and PGD2 in DLBCL was examined.

Main Results:

DLBCL patients exhibited high serum PGD2 concentrations and low CRTH2 expression, correlating with clinical features and prognosis.
Low-concentration PGD2 promoted DLBCL cell growth, while high-concentration PGD2 inhibited it by affecting proliferation, apoptosis, cell cycle, and invasion.
High-concentration PGD2 induced ROS-mediated DNA damage and enhanced the efficacy of adriamycin, bendamustine, and venetoclax.
HDAC inhibitors and a CRTH2 inhibitor modulated CRTH2 expression and PGD2 production, with synergistic anti-tumor effects observed with high-concentration PGD2.

Conclusions:

PGD2 and CRTH2 are identified as novel prognostic biomarkers in DLBCL.
High-concentration PGD2 demonstrates potential as a therapeutic strategy for DLBCL, enhancing drug cytotoxicity and anti-tumor effects.
Targeting PGD2 and CRTH2 pathways offers promising therapeutic avenues for DLBCL treatment.